Navigation Links
Edison Pharmaceuticals Receives Commendation From the City of San Jose

Mayor Chuck Reed recognizes contribution to city and children with rare


SAN JOSE, Calif., July 7 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held biotechnology company located in San Jose, CA, announced today the receipt of a commendation from the City of San Jose, acknowledging the company's contributions in fighting rare childhood diseases. The commendation recognizes "Edison for outstanding achievements in developing drugs for unmet medical need, and its commitment to public-private partnership, and extend our best wishes for many years of success in positively impacting the lives of children and individuals with mitochondrial diseases in America and throughout the world."

Mayor Chuck Reed and Councilmember Forrest Williams presented the commendation to Edison Chairman and CEO, Dr. Guy Miller on February 12th, 2008 at City Hall. "Since starting operations at the San Jose BioCenter in January 2006, Edison Pharmaceuticals has helped to make San Jose a center of life science technology. Edison is doing a remarkable job by focusing its R&D efforts on discovering a treatment for mitochondrial diseases -- that impair energy metabolism, and for which there exist no drugs," said Mayor Chuck Reed. "I congratulate Edison on achieving high performance standards and for the commitment of its founder Dr. Guy Miller and his team to improving the lives of children throughout the world."

About Edison Pharmaceuticals

Edison Pharmaceuticals, Inc., a biotechnology company based in Silicon Valley California at the San Jose Biocenter, is focused on developing drugs for rare diseases that impair energy metabolism. Edison possesses a technology platform and specialized knowledge in redox therapeutics -- pivotal to targeting genetic defects in the mitochondria. The Company's initial focus is on inherited diseases of the mitochondrial respiratory chain. The company is leveraging insights derived from those studies to pursue other diseases that share common mechanisms, such as Huntington's disease and diseases of aging. Edison has obtained substantial peer-reviewed grants from multiple foundations and the National Institutes of Health.

SOURCE Edison Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Edison Innovation Fund Helps Tris Pharma Expand
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time in ... STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, ... , US2020’s mission is to change the trajectory of STEM education in America ...
(Date:10/10/2017)... CALIFORNIA (PRWEB) , ... October 10, 2017 , ... ... technological innovation and business process optimization firm for the life sciences and healthcare ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation for ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board ... Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been selected ... member of the winning team for the 2015 Breakthrough Prize in Fundamental physics for ...
(Date:10/7/2017)... Seattle, WA (PRWEB) , ... ... ... the industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome ... the ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C ...
Breaking Biology Technology:
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at . 2016 Year Highlights: ...
Breaking Biology News(10 mins):